Recruiting Schizophrenia Studies in Lemon Grove
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg o...
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia...
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants age...
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 ...
About Schizophrenia Clinical Trials in Lemon Grove
Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.
There are currently 4 schizophrenia clinical trials recruiting participants in Lemon Grove, CALIFORNIA. These studies are seeking a combined 1,662 participants. Research is being sponsored by Reviva Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Inc., MapLight Therapeutics and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Schizophrenia Clinical Trials in Lemon Grove — FAQ
Are there schizophrenia clinical trials in Lemon Grove?
Yes, there are 4 schizophrenia clinical trials currently recruiting in Lemon Grove, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Lemon Grove?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lemon Grove research site will contact you about next steps.
Are clinical trials in Lemon Grove free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lemon Grove studies also compensate for your time and travel.
What schizophrenia treatments are being tested?
The 4 active trials in Lemon Grove are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.
Data updated March 2, 2026 from ClinicalTrials.gov